Novartis
Leqvio
page 1 of 4
4C
(near Familial
Hypercholesterolemia)
OF PATIENTS WERE FULLY ADHERENT
(PDC ≥0.8) TO EVOLOCUMAB OR ALIROCUMAB
vs
56%
IN A 12-MONTH ADHERENCE STUDY IN A REAL-WORLD SETTING1:
ASCVD, atherosclerotic cardiovascular disease; CI, confi dence interval; CVD, cardiovascular disease; HeFH, heterozygous familial hypercholesterolemia; HCP, health care 
professional; LDL-C, low-density lipoprotein cholesterol; mAb, monoclonal antibody; PCSK9, proprotein convertase subtilisin/kexin type 9; siRNA, small interfering 
ribonucleic acid; T2DM, type 2 diabetes mellitus.
 * Komodo Health, a nationally representative longitudinal database that captures 330 million patients in the US from open and closed administrative databases, was utilized 
from January 2021 to October 2023.
†PDC calculates the proportion of days a patient has access to their prescribed medication over a defi ned period of interest, which was 12 months for this study.
‡ The allowable dosing window for all treatments was added as per prescribing information. For LEQVIO +90 days, and for evolocumab and alirocumab +7 days.
§Data were adjusted to account for differences in baseline characteristics among cohorts.
Study design: A retrospective, observational real-world study evaluated 12-month adherence and persistence for newly initiated patients 
on LEQVIO (N=852), evolocumab (N=27,171), and alirocumab (N=8878) using administrative claims databases.* Adherence was defi ned as 
the proportion of days covered (PDC)†; fully adherent patients were defi ned as having a PDC of ≥0.8. Persistence was defi ned as patients 
on therapy for 12 months after index date with a ≤90-day gap for LEQVIO and ≤60-day gap for evolocumab and alirocumab between last 
day of supply and start of the next prescription.
PATIENTS ON PCSK9 mAbs MAY FACE 
CHALLENGES STAYING ON THERAPY

View this content as a flipbook by clicking here.